Haemonetics

Haemonetics (NYSE:HAE) shares ticked up before hours on first-quarter results that topped the consensus forecast.

Shares of HAE were up 5.1% at $71 apiece before the market opened. They continued to rise and were up 7.8% at $72.84 in early-morning trading.

The Boston-based hematology device company posted profits of $19.9 million, or 38¢ per share, on sales of $261.5 million for the three months ended July 2, 2022, for a massive bottom-line gain out of the red on sales growth of 14.4%.

Adjusted to exclude one-time items, earnings per share were 58¢, 7¢ ahead of Wall Street, where analysts were looking for sales of $249 million.

“Positive first-quarter results across businesses affirm our long-range plan for transformational growth,” Haemonetics CEO Chris Simon said in a news release. Robust growth in plasma is evidence of improving momentum in plasma collections and hospital is an increasingly powerful driver of growth, with vascular closure…

[Image from Haemonetics]Haemonetics (NYSE:HAE) announced today that it fully commenced operations at its new manufacturing center in Clinton, Pennsylvania.

Boston-based Haemonetics previously operated at a manufacturing plant in nearby Leetsdale, Pennsylvania, from 1990 until now.

According to a news release, the custom-built facility constitutes approximately 200,000 square feet in Clinton Commerce Park near Pittsburgh International Airport. Initial manufacturing began earlier this year at the site, with Haemonetics making use of both resources from the Leetsdale facility as well as new, advanced technology and manufacturing equipment to support demand for the production of disposables and consumables across its plasma and hospital businesses.

The Clinton facility also includes several environmentally-focused features, including smart controls on the HVAC systems, a recycled compressor heat system for more efficient temperature control and a closed loop pr…

Haemonetics (NYSE:HAE) this week appointed James D’Arecca as chief financial officer, effective on April 11.

D’Arecca will oversee the company’s treasury, controllership and accounting, investor relations, tax, information technology and financial planning and analysis functions. He will report directly to president and CEO Chris Simon. He succeeds William Burke who will remain with Haemonetics in an advisory role through June 30.

“Haemonetics is recognized and respected for its long history of innovation and industry leadership in improving standards of care. I am excited to help the Company continue to achieve strong results, accelerate growth, and expand its impact throughout the world,” D’Arecca said in a news release.

Prior to joining the company, D’Arecca was the chief financial officer of TherapeuticsMD. He previously served as senior VP and chief accounting officer at Allergan and held leadership roles at Bausch + Lo…

Haemonetics (NYSE:HAE) shares dipped slightly before hours on third-quarter results that were mixed compared to the consensus forecast.

The Boston-based company posted profits of $23.2 million, or 45¢ per share, on sales of $259.8 million for the three months ended Jan. 1, 2022, for a 27.1% bottom-line slide on sales growth of 8.1%.

Adjusted to exclude one-time items, earnings per share were 84¢, 11¢ ahead of Wall Street, where analysts were looking for sales of $266.7 million.

“Our third-quarter results reflect our agility and resilience in meeting the challenges of the pandemic on U.S. blood and plasma collections and some hospital products,” Haemonetics CEO Chris Simon said in a news release. “Plasma collections improved and we continued to convert customers to our latest NexSys and Persona technologies, while our hospital business delivered double-digit growth and a new record quarter for sales in hemostasis management and vascular closur…

Haemonetics today said that it has received FDA approval for same-day discharge after atrial fibrillation ablation using its Vascade MVP venous vascular closure system.

Vascade MVP is a vascular closure system that is designed for procedures that require multiple access site venous closures. It uses 6 to 12 Fr inner diameter sheaths that are commonly used in cardiac electrophysiology procedures to enable earlier ambulation, earlier discharge eligibility and a higher patient satisfaction, according to the Boston-based company.

“COVID has accelerated the need to enhance safety and efficacy to optimize the patient experience in meaningful ways. Vascade MVP earning the first and only indication for same-day discharge for AF ablation patients speaks to our industry leadership and continued commitment to improving the standards of care,” CEO and president Chris Simon said in a news release.

The same-day discharge labeling was granted following the …

Haemonetics (NYSE:HAE) posted first-quarter results this week that beat the overall consensus on Wall Street.

The Boston-based hematology device company reported losses of -$4.5 million, or -9¢ per share, on sales of $228.5 million for the three months ended July 3, for a sales growth of 16.85% compared with Q1 2021.

Adjusted to exclude one-time items, earnings per share were 50¢, 4¢ ahead of The Street, where analysts were looking for sales of $219.4 million.

“Our first-quarter performance is a positive start to the year, supported by recovery across all of our businesses, especially Hospital, and the initial Plasma Persona rollouts. We remain confident in the strong end-market demand for our products and continue to anticipate full recovery from the pandemic by the end of this fiscal year. Our revised Operational Excellence program will drive quality, service and greater productivity, while helping us to offset impacts of the anticipated customer loss,…

Haemonetics (NYSE:HAE) posted fourth-quarter results today that beat the revenue consensus on Wall Street and missed on earnings estimates.

The company reported losses of -$11 million, or -22¢ per share, on sales of $225 million for the three months ended April 3, for a sales loss of -5.65% compared with Q4 2021.

Adjusted to exclude one-time items, earnings per share were 46¢, 21¢ behind The Street, where analysts were looking for sales of $222.98 million.

“The pandemic affected fiscal 2021, particularly our plasma business, but cost mitigation efforts coupled with the Operational Excellence Program helped dampen the impact,” CEO Chris Simon said in a news release. “We took meaningful steps to position the company for growth, including the Persona launch, the Cardiva Medical acquisition, various divestitures and the debt refinancing.”

“We remain confident in the strong end-market demand for our products and expect ful…

Haemonetics (NYSE:HAE) posted third-quarter results today that beat the consensus forecast on Wall Street, sending its shares up.

The Boston-based company reported profits of $31.9 million, or 62¢ per share, on sales of $240.4 million for the three months ended Dec. 26, 2020, for a bottom-line gain of 6.6% sales loss of -7.2% compared with Q3 2020.

Adjusted to exclude one-time items, earnings per share were 81¢, 16¢ ahead of The Street, where analysts were looking for sales of $224.3 million.

“In the third quarter, revenue improved sequentially and productivity from our Operational Excellence Program and cost management helped improve profitability,” CEO Chris Simon said in a news release. “We are progressing with NexSys and TEG adoption and we are investing in our innovation agenda for future growth. The Cardiva Medical acquisition supports our strategy, diversifies our portfolio and is expected to create significant shareholder value.”

…